ABBV — long thesis
Thesis
AbbVie is a leading defensive healthcare name benefiting from the current rotation out of tech into healthcare. With April CPI at 3.8% (highest since May 2023) and rate cut expectations evaporating, investors are rotating into defensive sectors — healthcare led today's market at +2.1% while tech fell -2.4%. ABBV is up +2.6% today, demonstrating its defensive quality. The company has strong pipeline (Skyrizi, Rinvoq offsetting Humira declines), reasonable valuation for the pharma sector, and dividend support. Healthcare remains historically cheap relative to tech multiples, and the inflationary macro regime favors companies with pricing power and inelastic demand.
Triggers
Entry: Enter on any pullback to the $200-205 range, or if the tech-to-healthcare rotation continues for 3+ sessions confirming the trend. Position size ~1-2% of portfolio. Do not chase above $215.
Exit: Take profits at $230-240 (near consensus analyst targets). Exit if healthcare sector reverses and tech reclaims leadership for 5+ consecutive sessions. Trim if position exceeds 3% of portfolio.
Invalidation: Healthcare sector underperforms SPY for 2+ consecutive weeks; ABBV-specific pipeline setbacks (Skyrizi/Rinvoq growth decelerating); CPI reverses sharply below 3% removing the defensive rotation catalyst; stock breaks below $190 on fundamental concerns.
Cited evidence
Macro
- Sticky Inflation And Fed Rate Hike Fears Put These ETFs In The Spotlight
- 10 Health Care Stocks Whale Activity In Today's Session
- Nasdaq Dips Over 1%; US Inflation Surges To 3.8% In April